Point72 Asset Management
PRLD icon

Point72 Asset Management’s Prelude Therapeutics PRLD Stock Holding History

Point72 Asset Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$55.8K Sell
16,329
-42,839
-72% -$112K ﹤0.01% 3655
2025
Q4 		$172K Buy
+59,168
New +$99.8K ﹤0.01% 3669
2023
Q2 		– Sell
-1,222
Closed -$6.96K – 2664
2023
Q1 		$6.96K Buy
+1,222
New +$7.45K ﹤0.01% 2062
2020
Q4 		– Sell
-155,690
Closed -$4.69M – 1087
2020
Q3 		$4.69M Buy
+155,690
New +$4.4M 0.02% 579

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Point72 Asset Management's PRLD Position: Q1 2026 in Review

Point72 Asset Management reduced its Prelude Therapeutics (PRLD) stake by 72% in Q1 2026, selling an estimated $112K and leaving 16,329 shares worth $55.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3655.

Point72 Asset Management first reported a position in PRLD in Q3 2020 and has held it in 4 quarters since. The position peaked at $4.69M in Q3 2020. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • Point72 Asset Management held 16,329 shares of Prelude Therapeutics worth $55.8K as of Q1 2026.
  • Point72 Asset Management sold 42,839 Prelude Therapeutics shares in Q1 2026, an estimated $112K.
  • Prelude Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #3655 holding.
  • Point72 Asset Management first reported a position in Prelude Therapeutics in Q3 2020 and has held it in 4 quarters since.
  • Point72 Asset Management's Prelude Therapeutics position peaked at $4.69M in Q3 2020.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.